Global Ketorolac Injection Market Growth 2026-2032
The global Ketorolac Injection market size is predicted to grow from US$ 133 million in 2025 to US$ 193 million in 2032; it is expected to grow at a CAGR of 2.8% from 2026 to 2032.
Ketorolac tromethamine injection is a prescription injectable nonsteroidal anti-inflammatory drug (NSAID) for short-term analgesia. Its active ingredient is a salt formed from ketorolac and tromethamine. It exerts its analgesic effect (and also has some anti-inflammatory and antipyretic properties) primarily by inhibiting cyclooxygenase (COX) to reduce prostaglandin production. This drug is typically used for short-term treatment of moderate to severe acute pain (commonly in perioperative or emergency pain management). It is characterized by its strong analgesic effect and reduced need for opioids. However, like other NSAIDs, it carries important safety risks such as gastrointestinal bleeding/ulceration, renal impairment, and bleeding. Therefore, strict control of the course of treatment and dosage is emphasized in clinical practice, and it must be used according to contraindications (such as active gastrointestinal bleeding, severe renal insufficiency, and high perioperative bleeding risk).
The demand for ketorolac tromethamine injection is essentially driven by the scenario of 'short-term, intensive analgesia in hospitals.' At the label level, it is positioned as a short-term (maximum of 5 days for adults) tool for managing moderate to severe acute pain, achieving 'opioid-level analgesia requirements,' which aligns particularly well with the clinical pathways for perioperative and emergency acute pain. Simultaneously, the massive number of surgeries performed globally each year and the continuous standardization of perioperative management have made 'opioid-free/multimodal analgesia to reduce opioid use' a long-term trend, providing structural support for NSAID-based injectable analgesia. However, the market expansion of this product is naturally limited by its risk profile: the label explicitly emphasizes several important contraindications and warnings, including renal risk, bleeding risk, and contraindication in CABG surgery. Hospital medication management will more strongly constrain its use within the boundaries of 'short treatment course, controllable population, and monitorable risk.'
From a competitive landscape perspective, ketorolac injection represents a typical combination of a 'mature, generic product + high barriers to entry in sterile injectable manufacturing': brand differentiation is limited, with competition primarily focused on sterile production and quality system capabilities, stable supply capabilities, packaging formats, and hospital compliance support (such as single-dose vials, barcodes and hospital dispensing friendliness, and channel coverage). In markets like the US, publicly available data shows that this product is supplied by multiple companies under different NDC/packaging company identities, including large generic injectable platforms (such as Pfizer and Fresenius Kabi) as well as multiple generic drug companies and packaging/distribution entities (such as Sun and Sagent), reflecting a multi-layered supply chain and price competition. For buyers (hospitals/group purchasing), evaluation dimensions often shift from 'efficacy differences' to 'supply disruption risk, compliance documentation, batch-to-batch consistency, and recall and change control history,' which explains why manufacturing and quality management are given greater emphasis in procurement and market access for this type of product.
North America is the largest market, with a share about 40%, followed by Asia-Pacific and Europe with the share about 27% and 20%. In terms of product, 30mg/ml ketorolac injection is the largest segment, with a share over 64%. And in terms of application, the largest application is hospital, followed by clinics.
Future growth is more likely to stem from changes in 'clinical pathways and delivery methods' rather than new selling points at the pharmacological level. On the one hand, the strengthening of multimodal analgesia in guidelines and academic consensus will drive hospitals to continuously optimize perioperative analgesia combinations and increase the weighting of non-opioid analgesia. Evidence is also accumulating regarding the effectiveness of NSAIDs in reducing postoperative pain and opioid usage when combined with regional anesthesia and glucocorticoids. On the other hand, safety and compliance requirements will continue to shape the market: the 5-day treatment limit and warnings about bleeding/kidney risk make it more suitable as a short-term tool rather than a long-term medication. Hospitals may place greater emphasis on tiered medication, perioperative bleeding risk management, and kidney function monitoring, thereby prompting companies to invest more in compliance with instructions, risk communication, and real-world medication management support. Meanwhile, given the frequent disruptions to the sterile injectable supply chain, suppliers that can provide more 'ready-to-use/less error-prone' packaging specifications and have stable production capacity and consistent quality have a greater chance of gaining an advantage in centralized procurement/hospital access.
LP Information, Inc. (LPI) ' newest research report, the ?Ketorolac Injection Industry Forecast? looks at past sales and reviews total world Ketorolac Injection sales in 2025, providing a comprehensive analysis by region and market sector of projected Ketorolac Injection sales for 2026 through 2032. With Ketorolac Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Ketorolac Injection industry.
This Insight Report provides a comprehensive analysis of the global Ketorolac Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Ketorolac Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Ketorolac Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ketorolac Injection and breaks down the forecast by Concentration, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ketorolac Injection.
This report presents a comprehensive overview, market shares, and growth opportunities of Ketorolac Injection market by product type, application, key manufacturers and key regions and countries.
Segmentation by Concentration:
Ketorolac tromethamine injection is a prescription injectable nonsteroidal anti-inflammatory drug (NSAID) for short-term analgesia. Its active ingredient is a salt formed from ketorolac and tromethamine. It exerts its analgesic effect (and also has some anti-inflammatory and antipyretic properties) primarily by inhibiting cyclooxygenase (COX) to reduce prostaglandin production. This drug is typically used for short-term treatment of moderate to severe acute pain (commonly in perioperative or emergency pain management). It is characterized by its strong analgesic effect and reduced need for opioids. However, like other NSAIDs, it carries important safety risks such as gastrointestinal bleeding/ulceration, renal impairment, and bleeding. Therefore, strict control of the course of treatment and dosage is emphasized in clinical practice, and it must be used according to contraindications (such as active gastrointestinal bleeding, severe renal insufficiency, and high perioperative bleeding risk).
The demand for ketorolac tromethamine injection is essentially driven by the scenario of 'short-term, intensive analgesia in hospitals.' At the label level, it is positioned as a short-term (maximum of 5 days for adults) tool for managing moderate to severe acute pain, achieving 'opioid-level analgesia requirements,' which aligns particularly well with the clinical pathways for perioperative and emergency acute pain. Simultaneously, the massive number of surgeries performed globally each year and the continuous standardization of perioperative management have made 'opioid-free/multimodal analgesia to reduce opioid use' a long-term trend, providing structural support for NSAID-based injectable analgesia. However, the market expansion of this product is naturally limited by its risk profile: the label explicitly emphasizes several important contraindications and warnings, including renal risk, bleeding risk, and contraindication in CABG surgery. Hospital medication management will more strongly constrain its use within the boundaries of 'short treatment course, controllable population, and monitorable risk.'
From a competitive landscape perspective, ketorolac injection represents a typical combination of a 'mature, generic product + high barriers to entry in sterile injectable manufacturing': brand differentiation is limited, with competition primarily focused on sterile production and quality system capabilities, stable supply capabilities, packaging formats, and hospital compliance support (such as single-dose vials, barcodes and hospital dispensing friendliness, and channel coverage). In markets like the US, publicly available data shows that this product is supplied by multiple companies under different NDC/packaging company identities, including large generic injectable platforms (such as Pfizer and Fresenius Kabi) as well as multiple generic drug companies and packaging/distribution entities (such as Sun and Sagent), reflecting a multi-layered supply chain and price competition. For buyers (hospitals/group purchasing), evaluation dimensions often shift from 'efficacy differences' to 'supply disruption risk, compliance documentation, batch-to-batch consistency, and recall and change control history,' which explains why manufacturing and quality management are given greater emphasis in procurement and market access for this type of product.
North America is the largest market, with a share about 40%, followed by Asia-Pacific and Europe with the share about 27% and 20%. In terms of product, 30mg/ml ketorolac injection is the largest segment, with a share over 64%. And in terms of application, the largest application is hospital, followed by clinics.
Future growth is more likely to stem from changes in 'clinical pathways and delivery methods' rather than new selling points at the pharmacological level. On the one hand, the strengthening of multimodal analgesia in guidelines and academic consensus will drive hospitals to continuously optimize perioperative analgesia combinations and increase the weighting of non-opioid analgesia. Evidence is also accumulating regarding the effectiveness of NSAIDs in reducing postoperative pain and opioid usage when combined with regional anesthesia and glucocorticoids. On the other hand, safety and compliance requirements will continue to shape the market: the 5-day treatment limit and warnings about bleeding/kidney risk make it more suitable as a short-term tool rather than a long-term medication. Hospitals may place greater emphasis on tiered medication, perioperative bleeding risk management, and kidney function monitoring, thereby prompting companies to invest more in compliance with instructions, risk communication, and real-world medication management support. Meanwhile, given the frequent disruptions to the sterile injectable supply chain, suppliers that can provide more 'ready-to-use/less error-prone' packaging specifications and have stable production capacity and consistent quality have a greater chance of gaining an advantage in centralized procurement/hospital access.
LP Information, Inc. (LPI) ' newest research report, the ?Ketorolac Injection Industry Forecast? looks at past sales and reviews total world Ketorolac Injection sales in 2025, providing a comprehensive analysis by region and market sector of projected Ketorolac Injection sales for 2026 through 2032. With Ketorolac Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Ketorolac Injection industry.
This Insight Report provides a comprehensive analysis of the global Ketorolac Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Ketorolac Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Ketorolac Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ketorolac Injection and breaks down the forecast by Concentration, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ketorolac Injection.
This report presents a comprehensive overview, market shares, and growth opportunities of Ketorolac Injection market by product type, application, key manufacturers and key regions and countries.
Segmentation by Concentration:
- 15mg/ml
- 30mg/ml
- Hospital
- Clinics
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Pfizer
- Fresenius Kabi
- Sun Pharmaceutical
- Sagent Pharmaceuticals
- Baxter
- Glenmark Pharmaceutical
- Sola Pharmaceutical
- TC Pharmaceuticals (Jiangsu) Co., Ltd
- Lunan Pharm
- Yunnan Longhai Natured Plant Pharmaceutical
- Hairon Pharma
- Sichuan Medcalo
- Chengdu Brilliant Pharmaceuticals
- Yung Shin Pharm
- Tianjin Chase Sun Pharmaceutical
- ZISKA Pharmaceuticals
- What is the 10-year outlook for the global Ketorolac Injection market?
- What factors are driving Ketorolac Injection market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Ketorolac Injection market opportunities vary by end market size?
- How does Ketorolac Injection break out by Concentration, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Ketorolac Injection Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Ketorolac Injection by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Ketorolac Injection by Country/Region, 2021, 2025 & 2032
2.2 Ketorolac Injection Segment by Concentration
2.2.1 15mg/ml
2.2.2 30mg/ml
2.2.3 Ketorolac Injection Sales by Concentration
2.2.3.1 Global Ketorolac Injection Sales Market Share by Concentration (2021-2026)
2.2.3.2 Global Ketorolac Injection Revenue and Market Share by Concentration (2021-2026)
2.2.3.3 Global Ketorolac Injection Sale Price by Concentration (2021-2026)
2.3 Ketorolac Injection Segment by Application
2.3.1 Hospital
2.3.2 Clinics
2.3.3 Others
2.3.4 Ketorolac Injection Sales by Application
2.3.4.1 Global Ketorolac Injection Sale Market Share by Application (2021-2026)
2.3.4.2 Global Ketorolac Injection Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Ketorolac Injection Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Ketorolac Injection Breakdown Data by Company
3.1.1 Global Ketorolac Injection Annual Sales by Company (2021-2026)
3.1.2 Global Ketorolac Injection Sales Market Share by Company (2021-2026)
3.2 Global Ketorolac Injection Annual Revenue by Company (2021-2026)
3.2.1 Global Ketorolac Injection Revenue by Company (2021-2026)
3.2.2 Global Ketorolac Injection Revenue Market Share by Company (2021-2026)
3.3 Global Ketorolac Injection Sale Price by Company
3.4 Key Manufacturers Ketorolac Injection Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Ketorolac Injection Product Location Distribution
3.4.2 Players Ketorolac Injection Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR KETOROLAC INJECTION BY GEOGRAPHIC REGION
4.1 World Historic Ketorolac Injection Market Size by Geographic Region (2021-2026)
4.1.1 Global Ketorolac Injection Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Ketorolac Injection Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Ketorolac Injection Market Size by Country/Region (2021-2026)
4.2.1 Global Ketorolac Injection Annual Sales by Country/Region (2021-2026)
4.2.2 Global Ketorolac Injection Annual Revenue by Country/Region (2021-2026)
4.3 Americas Ketorolac Injection Sales Growth
4.4 APAC Ketorolac Injection Sales Growth
4.5 Europe Ketorolac Injection Sales Growth
4.6 Middle East & Africa Ketorolac Injection Sales Growth
5 AMERICAS
5.1 Americas Ketorolac Injection Sales by Country
5.1.1 Americas Ketorolac Injection Sales by Country (2021-2026)
5.1.2 Americas Ketorolac Injection Revenue by Country (2021-2026)
5.2 Americas Ketorolac Injection Sales by Concentration (2021-2026)
5.3 Americas Ketorolac Injection Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Ketorolac Injection Sales by Region
6.1.1 APAC Ketorolac Injection Sales by Region (2021-2026)
6.1.2 APAC Ketorolac Injection Revenue by Region (2021-2026)
6.2 APAC Ketorolac Injection Sales by Concentration (2021-2026)
6.3 APAC Ketorolac Injection Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Ketorolac Injection by Country
7.1.1 Europe Ketorolac Injection Sales by Country (2021-2026)
7.1.2 Europe Ketorolac Injection Revenue by Country (2021-2026)
7.2 Europe Ketorolac Injection Sales by Concentration (2021-2026)
7.3 Europe Ketorolac Injection Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Ketorolac Injection by Country
8.1.1 Middle East & Africa Ketorolac Injection Sales by Country (2021-2026)
8.1.2 Middle East & Africa Ketorolac Injection Revenue by Country (2021-2026)
8.2 Middle East & Africa Ketorolac Injection Sales by Concentration (2021-2026)
8.3 Middle East & Africa Ketorolac Injection Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Ketorolac Injection
10.3 Manufacturing Process Analysis of Ketorolac Injection
10.4 Industry Chain Structure of Ketorolac Injection
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Ketorolac Injection Distributors
11.3 Ketorolac Injection Customer
12 WORLD FORECAST REVIEW FOR KETOROLAC INJECTION BY GEOGRAPHIC REGION
12.1 Global Ketorolac Injection Market Size Forecast by Region
12.1.1 Global Ketorolac Injection Forecast by Region (2027-2032)
12.1.2 Global Ketorolac Injection Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Ketorolac Injection Forecast by Concentration (2027-2032)
12.7 Global Ketorolac Injection Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Ketorolac Injection Product Portfolios and Specifications
13.1.3 Pfizer Ketorolac Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Fresenius Kabi
13.2.1 Fresenius Kabi Company Information
13.2.2 Fresenius Kabi Ketorolac Injection Product Portfolios and Specifications
13.2.3 Fresenius Kabi Ketorolac Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Fresenius Kabi Main Business Overview
13.2.5 Fresenius Kabi Latest Developments
13.3 Sun Pharmaceutical
13.3.1 Sun Pharmaceutical Company Information
13.3.2 Sun Pharmaceutical Ketorolac Injection Product Portfolios and Specifications
13.3.3 Sun Pharmaceutical Ketorolac Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Sun Pharmaceutical Main Business Overview
13.3.5 Sun Pharmaceutical Latest Developments
13.4 Sagent Pharmaceuticals
13.4.1 Sagent Pharmaceuticals Company Information
13.4.2 Sagent Pharmaceuticals Ketorolac Injection Product Portfolios and Specifications
13.4.3 Sagent Pharmaceuticals Ketorolac Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Sagent Pharmaceuticals Main Business Overview
13.4.5 Sagent Pharmaceuticals Latest Developments
13.5 Baxter
13.5.1 Baxter Company Information
13.5.2 Baxter Ketorolac Injection Product Portfolios and Specifications
13.5.3 Baxter Ketorolac Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Baxter Main Business Overview
13.5.5 Baxter Latest Developments
13.6 Glenmark Pharmaceutical
13.6.1 Glenmark Pharmaceutical Company Information
13.6.2 Glenmark Pharmaceutical Ketorolac Injection Product Portfolios and Specifications
13.6.3 Glenmark Pharmaceutical Ketorolac Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Glenmark Pharmaceutical Main Business Overview
13.6.5 Glenmark Pharmaceutical Latest Developments
13.7 Sola Pharmaceutical
13.7.1 Sola Pharmaceutical Company Information
13.7.2 Sola Pharmaceutical Ketorolac Injection Product Portfolios and Specifications
13.7.3 Sola Pharmaceutical Ketorolac Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Sola Pharmaceutical Main Business Overview
13.7.5 Sola Pharmaceutical Latest Developments
13.8 TC Pharmaceuticals (Jiangsu) Co., Ltd
13.8.1 TC Pharmaceuticals (Jiangsu) Co., Ltd Company Information
13.8.2 TC Pharmaceuticals (Jiangsu) Co., Ltd Ketorolac Injection Product Portfolios and Specifications
13.8.3 TC Pharmaceuticals (Jiangsu) Co., Ltd Ketorolac Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 TC Pharmaceuticals (Jiangsu) Co., Ltd Main Business Overview
13.8.5 TC Pharmaceuticals (Jiangsu) Co., Ltd Latest Developments
13.9 Lunan Pharm
13.9.1 Lunan Pharm Company Information
13.9.2 Lunan Pharm Ketorolac Injection Product Portfolios and Specifications
13.9.3 Lunan Pharm Ketorolac Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Lunan Pharm Main Business Overview
13.9.5 Lunan Pharm Latest Developments
13.10 Yunnan Longhai Natured Plant Pharmaceutical
13.10.1 Yunnan Longhai Natured Plant Pharmaceutical Company Information
13.10.2 Yunnan Longhai Natured Plant Pharmaceutical Ketorolac Injection Product Portfolios and Specifications
13.10.3 Yunnan Longhai Natured Plant Pharmaceutical Ketorolac Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Yunnan Longhai Natured Plant Pharmaceutical Main Business Overview
13.10.5 Yunnan Longhai Natured Plant Pharmaceutical Latest Developments
13.11 Hairon Pharma
13.11.1 Hairon Pharma Company Information
13.11.2 Hairon Pharma Ketorolac Injection Product Portfolios and Specifications
13.11.3 Hairon Pharma Ketorolac Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Hairon Pharma Main Business Overview
13.11.5 Hairon Pharma Latest Developments
13.12 Sichuan Medcalo
13.12.1 Sichuan Medcalo Company Information
13.12.2 Sichuan Medcalo Ketorolac Injection Product Portfolios and Specifications
13.12.3 Sichuan Medcalo Ketorolac Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Sichuan Medcalo Main Business Overview
13.12.5 Sichuan Medcalo Latest Developments
13.13 Chengdu Brilliant Pharmaceuticals
13.13.1 Chengdu Brilliant Pharmaceuticals Company Information
13.13.2 Chengdu Brilliant Pharmaceuticals Ketorolac Injection Product Portfolios and Specifications
13.13.3 Chengdu Brilliant Pharmaceuticals Ketorolac Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Chengdu Brilliant Pharmaceuticals Main Business Overview
13.13.5 Chengdu Brilliant Pharmaceuticals Latest Developments
13.14 Yung Shin Pharm
13.14.1 Yung Shin Pharm Company Information
13.14.2 Yung Shin Pharm Ketorolac Injection Product Portfolios and Specifications
13.14.3 Yung Shin Pharm Ketorolac Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Yung Shin Pharm Main Business Overview
13.14.5 Yung Shin Pharm Latest Developments
13.15 Tianjin Chase Sun Pharmaceutical
13.15.1 Tianjin Chase Sun Pharmaceutical Company Information
13.15.2 Tianjin Chase Sun Pharmaceutical Ketorolac Injection Product Portfolios and Specifications
13.15.3 Tianjin Chase Sun Pharmaceutical Ketorolac Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Tianjin Chase Sun Pharmaceutical Main Business Overview
13.15.5 Tianjin Chase Sun Pharmaceutical Latest Developments
13.16 ZISKA Pharmaceuticals
13.16.1 ZISKA Pharmaceuticals Company Information
13.16.2 ZISKA Pharmaceuticals Ketorolac Injection Product Portfolios and Specifications
13.16.3 ZISKA Pharmaceuticals Ketorolac Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 ZISKA Pharmaceuticals Main Business Overview
13.16.5 ZISKA Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Ketorolac Injection Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Ketorolac Injection by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Ketorolac Injection by Country/Region, 2021, 2025 & 2032
2.2 Ketorolac Injection Segment by Concentration
2.2.1 15mg/ml
2.2.2 30mg/ml
2.2.3 Ketorolac Injection Sales by Concentration
2.2.3.1 Global Ketorolac Injection Sales Market Share by Concentration (2021-2026)
2.2.3.2 Global Ketorolac Injection Revenue and Market Share by Concentration (2021-2026)
2.2.3.3 Global Ketorolac Injection Sale Price by Concentration (2021-2026)
2.3 Ketorolac Injection Segment by Application
2.3.1 Hospital
2.3.2 Clinics
2.3.3 Others
2.3.4 Ketorolac Injection Sales by Application
2.3.4.1 Global Ketorolac Injection Sale Market Share by Application (2021-2026)
2.3.4.2 Global Ketorolac Injection Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Ketorolac Injection Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Ketorolac Injection Breakdown Data by Company
3.1.1 Global Ketorolac Injection Annual Sales by Company (2021-2026)
3.1.2 Global Ketorolac Injection Sales Market Share by Company (2021-2026)
3.2 Global Ketorolac Injection Annual Revenue by Company (2021-2026)
3.2.1 Global Ketorolac Injection Revenue by Company (2021-2026)
3.2.2 Global Ketorolac Injection Revenue Market Share by Company (2021-2026)
3.3 Global Ketorolac Injection Sale Price by Company
3.4 Key Manufacturers Ketorolac Injection Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Ketorolac Injection Product Location Distribution
3.4.2 Players Ketorolac Injection Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR KETOROLAC INJECTION BY GEOGRAPHIC REGION
4.1 World Historic Ketorolac Injection Market Size by Geographic Region (2021-2026)
4.1.1 Global Ketorolac Injection Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Ketorolac Injection Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Ketorolac Injection Market Size by Country/Region (2021-2026)
4.2.1 Global Ketorolac Injection Annual Sales by Country/Region (2021-2026)
4.2.2 Global Ketorolac Injection Annual Revenue by Country/Region (2021-2026)
4.3 Americas Ketorolac Injection Sales Growth
4.4 APAC Ketorolac Injection Sales Growth
4.5 Europe Ketorolac Injection Sales Growth
4.6 Middle East & Africa Ketorolac Injection Sales Growth
5 AMERICAS
5.1 Americas Ketorolac Injection Sales by Country
5.1.1 Americas Ketorolac Injection Sales by Country (2021-2026)
5.1.2 Americas Ketorolac Injection Revenue by Country (2021-2026)
5.2 Americas Ketorolac Injection Sales by Concentration (2021-2026)
5.3 Americas Ketorolac Injection Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Ketorolac Injection Sales by Region
6.1.1 APAC Ketorolac Injection Sales by Region (2021-2026)
6.1.2 APAC Ketorolac Injection Revenue by Region (2021-2026)
6.2 APAC Ketorolac Injection Sales by Concentration (2021-2026)
6.3 APAC Ketorolac Injection Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Ketorolac Injection by Country
7.1.1 Europe Ketorolac Injection Sales by Country (2021-2026)
7.1.2 Europe Ketorolac Injection Revenue by Country (2021-2026)
7.2 Europe Ketorolac Injection Sales by Concentration (2021-2026)
7.3 Europe Ketorolac Injection Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Ketorolac Injection by Country
8.1.1 Middle East & Africa Ketorolac Injection Sales by Country (2021-2026)
8.1.2 Middle East & Africa Ketorolac Injection Revenue by Country (2021-2026)
8.2 Middle East & Africa Ketorolac Injection Sales by Concentration (2021-2026)
8.3 Middle East & Africa Ketorolac Injection Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Ketorolac Injection
10.3 Manufacturing Process Analysis of Ketorolac Injection
10.4 Industry Chain Structure of Ketorolac Injection
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Ketorolac Injection Distributors
11.3 Ketorolac Injection Customer
12 WORLD FORECAST REVIEW FOR KETOROLAC INJECTION BY GEOGRAPHIC REGION
12.1 Global Ketorolac Injection Market Size Forecast by Region
12.1.1 Global Ketorolac Injection Forecast by Region (2027-2032)
12.1.2 Global Ketorolac Injection Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Ketorolac Injection Forecast by Concentration (2027-2032)
12.7 Global Ketorolac Injection Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Ketorolac Injection Product Portfolios and Specifications
13.1.3 Pfizer Ketorolac Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Fresenius Kabi
13.2.1 Fresenius Kabi Company Information
13.2.2 Fresenius Kabi Ketorolac Injection Product Portfolios and Specifications
13.2.3 Fresenius Kabi Ketorolac Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Fresenius Kabi Main Business Overview
13.2.5 Fresenius Kabi Latest Developments
13.3 Sun Pharmaceutical
13.3.1 Sun Pharmaceutical Company Information
13.3.2 Sun Pharmaceutical Ketorolac Injection Product Portfolios and Specifications
13.3.3 Sun Pharmaceutical Ketorolac Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Sun Pharmaceutical Main Business Overview
13.3.5 Sun Pharmaceutical Latest Developments
13.4 Sagent Pharmaceuticals
13.4.1 Sagent Pharmaceuticals Company Information
13.4.2 Sagent Pharmaceuticals Ketorolac Injection Product Portfolios and Specifications
13.4.3 Sagent Pharmaceuticals Ketorolac Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Sagent Pharmaceuticals Main Business Overview
13.4.5 Sagent Pharmaceuticals Latest Developments
13.5 Baxter
13.5.1 Baxter Company Information
13.5.2 Baxter Ketorolac Injection Product Portfolios and Specifications
13.5.3 Baxter Ketorolac Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Baxter Main Business Overview
13.5.5 Baxter Latest Developments
13.6 Glenmark Pharmaceutical
13.6.1 Glenmark Pharmaceutical Company Information
13.6.2 Glenmark Pharmaceutical Ketorolac Injection Product Portfolios and Specifications
13.6.3 Glenmark Pharmaceutical Ketorolac Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Glenmark Pharmaceutical Main Business Overview
13.6.5 Glenmark Pharmaceutical Latest Developments
13.7 Sola Pharmaceutical
13.7.1 Sola Pharmaceutical Company Information
13.7.2 Sola Pharmaceutical Ketorolac Injection Product Portfolios and Specifications
13.7.3 Sola Pharmaceutical Ketorolac Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Sola Pharmaceutical Main Business Overview
13.7.5 Sola Pharmaceutical Latest Developments
13.8 TC Pharmaceuticals (Jiangsu) Co., Ltd
13.8.1 TC Pharmaceuticals (Jiangsu) Co., Ltd Company Information
13.8.2 TC Pharmaceuticals (Jiangsu) Co., Ltd Ketorolac Injection Product Portfolios and Specifications
13.8.3 TC Pharmaceuticals (Jiangsu) Co., Ltd Ketorolac Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 TC Pharmaceuticals (Jiangsu) Co., Ltd Main Business Overview
13.8.5 TC Pharmaceuticals (Jiangsu) Co., Ltd Latest Developments
13.9 Lunan Pharm
13.9.1 Lunan Pharm Company Information
13.9.2 Lunan Pharm Ketorolac Injection Product Portfolios and Specifications
13.9.3 Lunan Pharm Ketorolac Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Lunan Pharm Main Business Overview
13.9.5 Lunan Pharm Latest Developments
13.10 Yunnan Longhai Natured Plant Pharmaceutical
13.10.1 Yunnan Longhai Natured Plant Pharmaceutical Company Information
13.10.2 Yunnan Longhai Natured Plant Pharmaceutical Ketorolac Injection Product Portfolios and Specifications
13.10.3 Yunnan Longhai Natured Plant Pharmaceutical Ketorolac Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Yunnan Longhai Natured Plant Pharmaceutical Main Business Overview
13.10.5 Yunnan Longhai Natured Plant Pharmaceutical Latest Developments
13.11 Hairon Pharma
13.11.1 Hairon Pharma Company Information
13.11.2 Hairon Pharma Ketorolac Injection Product Portfolios and Specifications
13.11.3 Hairon Pharma Ketorolac Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Hairon Pharma Main Business Overview
13.11.5 Hairon Pharma Latest Developments
13.12 Sichuan Medcalo
13.12.1 Sichuan Medcalo Company Information
13.12.2 Sichuan Medcalo Ketorolac Injection Product Portfolios and Specifications
13.12.3 Sichuan Medcalo Ketorolac Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Sichuan Medcalo Main Business Overview
13.12.5 Sichuan Medcalo Latest Developments
13.13 Chengdu Brilliant Pharmaceuticals
13.13.1 Chengdu Brilliant Pharmaceuticals Company Information
13.13.2 Chengdu Brilliant Pharmaceuticals Ketorolac Injection Product Portfolios and Specifications
13.13.3 Chengdu Brilliant Pharmaceuticals Ketorolac Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Chengdu Brilliant Pharmaceuticals Main Business Overview
13.13.5 Chengdu Brilliant Pharmaceuticals Latest Developments
13.14 Yung Shin Pharm
13.14.1 Yung Shin Pharm Company Information
13.14.2 Yung Shin Pharm Ketorolac Injection Product Portfolios and Specifications
13.14.3 Yung Shin Pharm Ketorolac Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Yung Shin Pharm Main Business Overview
13.14.5 Yung Shin Pharm Latest Developments
13.15 Tianjin Chase Sun Pharmaceutical
13.15.1 Tianjin Chase Sun Pharmaceutical Company Information
13.15.2 Tianjin Chase Sun Pharmaceutical Ketorolac Injection Product Portfolios and Specifications
13.15.3 Tianjin Chase Sun Pharmaceutical Ketorolac Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Tianjin Chase Sun Pharmaceutical Main Business Overview
13.15.5 Tianjin Chase Sun Pharmaceutical Latest Developments
13.16 ZISKA Pharmaceuticals
13.16.1 ZISKA Pharmaceuticals Company Information
13.16.2 ZISKA Pharmaceuticals Ketorolac Injection Product Portfolios and Specifications
13.16.3 ZISKA Pharmaceuticals Ketorolac Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 ZISKA Pharmaceuticals Main Business Overview
13.16.5 ZISKA Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Ketorolac Injection Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Ketorolac Injection Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of 15mg/ml
Table 4. Major Players of 30mg/ml
Table 5. Global Ketorolac Injection Sales by Concentration (2021-2026) & (K Units)
Table 6. Global Ketorolac Injection Sales Market Share by Concentration (2021-2026)
Table 7. Global Ketorolac Injection Revenue by Concentration (2021-2026) & ($ million)
Table 8. Global Ketorolac Injection Revenue Market Share by Concentration (2021-2026)
Table 9. Global Ketorolac Injection Sale Price by Concentration (2021-2026) & (US$/Unit)
Table 10. Global Ketorolac Injection Sale by Application (2021-2026) & (K Units)
Table 11. Global Ketorolac Injection Sale Market Share by Application (2021-2026)
Table 12. Global Ketorolac Injection Revenue by Application (2021-2026) & ($ million)
Table 13. Global Ketorolac Injection Revenue Market Share by Application (2021-2026)
Table 14. Global Ketorolac Injection Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Ketorolac Injection Sales by Company (2021-2026) & (K Units)
Table 16. Global Ketorolac Injection Sales Market Share by Company (2021-2026)
Table 17. Global Ketorolac Injection Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Ketorolac Injection Revenue Market Share by Company (2021-2026)
Table 19. Global Ketorolac Injection Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Ketorolac Injection Producing Area Distribution and Sales Area
Table 21. Players Ketorolac Injection Products Offered
Table 22. Ketorolac Injection Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Ketorolac Injection Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Ketorolac Injection Sales Market Share Geographic Region (2021-2026)
Table 27. Global Ketorolac Injection Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Ketorolac Injection Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Ketorolac Injection Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Ketorolac Injection Sales Market Share by Country/Region (2021-2026)
Table 31. Global Ketorolac Injection Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Ketorolac Injection Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Ketorolac Injection Sales by Country (2021-2026) & (K Units)
Table 34. Americas Ketorolac Injection Sales Market Share by Country (2021-2026)
Table 35. Americas Ketorolac Injection Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Ketorolac Injection Sales by Concentration (2021-2026) & (K Units)
Table 37. Americas Ketorolac Injection Sales by Application (2021-2026) & (K Units)
Table 38. APAC Ketorolac Injection Sales by Region (2021-2026) & (K Units)
Table 39. APAC Ketorolac Injection Sales Market Share by Region (2021-2026)
Table 40. APAC Ketorolac Injection Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Ketorolac Injection Sales by Concentration (2021-2026) & (K Units)
Table 42. APAC Ketorolac Injection Sales by Application (2021-2026) & (K Units)
Table 43. Europe Ketorolac Injection Sales by Country (2021-2026) & (K Units)
Table 44. Europe Ketorolac Injection Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Ketorolac Injection Sales by Concentration (2021-2026) & (K Units)
Table 46. Europe Ketorolac Injection Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Ketorolac Injection Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Ketorolac Injection Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Ketorolac Injection Sales by Concentration (2021-2026) & (K Units)
Table 50. Middle East & Africa Ketorolac Injection Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Ketorolac Injection
Table 52. Key Market Challenges & Risks of Ketorolac Injection
Table 53. Key Industry Trends of Ketorolac Injection
Table 54. Ketorolac Injection Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Ketorolac Injection Distributors List
Table 57. Ketorolac Injection Customer List
Table 58. Global Ketorolac Injection Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Ketorolac Injection Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Ketorolac Injection Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Ketorolac Injection Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Ketorolac Injection Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Ketorolac Injection Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Ketorolac Injection Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Ketorolac Injection Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Ketorolac Injection Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Ketorolac Injection Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Ketorolac Injection Sales Forecast by Concentration (2027-2032) & (K Units)
Table 69. Global Ketorolac Injection Revenue Forecast by Concentration (2027-2032) & ($ millions)
Table 70. Global Ketorolac Injection Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Ketorolac Injection Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Pfizer Basic Information, Ketorolac Injection Manufacturing Base, Sales Area and Its Competitors
Table 73. Pfizer Ketorolac Injection Product Portfolios and Specifications
Table 74. Pfizer Ketorolac Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Pfizer Main Business
Table 76. Pfizer Latest Developments
Table 77. Fresenius Kabi Basic Information, Ketorolac Injection Manufacturing Base, Sales Area and Its Competitors
Table 78. Fresenius Kabi Ketorolac Injection Product Portfolios and Specifications
Table 79. Fresenius Kabi Ketorolac Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Fresenius Kabi Main Business
Table 81. Fresenius Kabi Latest Developments
Table 82. Sun Pharmaceutical Basic Information, Ketorolac Injection Manufacturing Base, Sales Area and Its Competitors
Table 83. Sun Pharmaceutical Ketorolac Injection Product Portfolios and Specifications
Table 84. Sun Pharmaceutical Ketorolac Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Sun Pharmaceutical Main Business
Table 86. Sun Pharmaceutical Latest Developments
Table 87. Sagent Pharmaceuticals Basic Information, Ketorolac Injection Manufacturing Base, Sales Area and Its Competitors
Table 88. Sagent Pharmaceuticals Ketorolac Injection Product Portfolios and Specifications
Table 89. Sagent Pharmaceuticals Ketorolac Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Sagent Pharmaceuticals Main Business
Table 91. Sagent Pharmaceuticals Latest Developments
Table 92. Baxter Basic Information, Ketorolac Injection Manufacturing Base, Sales Area and Its Competitors
Table 93. Baxter Ketorolac Injection Product Portfolios and Specifications
Table 94. Baxter Ketorolac Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Baxter Main Business
Table 96. Baxter Latest Developments
Table 97. Glenmark Pharmaceutical Basic Information, Ketorolac Injection Manufacturing Base, Sales Area and Its Competitors
Table 98. Glenmark Pharmaceutical Ketorolac Injection Product Portfolios and Specifications
Table 99. Glenmark Pharmaceutical Ketorolac Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Glenmark Pharmaceutical Main Business
Table 101. Glenmark Pharmaceutical Latest Developments
Table 102. Sola Pharmaceutical Basic Information, Ketorolac Injection Manufacturing Base, Sales Area and Its Competitors
Table 103. Sola Pharmaceutical Ketorolac Injection Product Portfolios and Specifications
Table 104. Sola Pharmaceutical Ketorolac Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. Sola Pharmaceutical Main Business
Table 106. Sola Pharmaceutical Latest Developments
Table 107. TC Pharmaceuticals (Jiangsu) Co., Ltd Basic Information, Ketorolac Injection Manufacturing Base, Sales Area and Its Competitors
Table 108. TC Pharmaceuticals (Jiangsu) Co., Ltd Ketorolac Injection Product Portfolios and Specifications
Table 109. TC Pharmaceuticals (Jiangsu) Co., Ltd Ketorolac Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. TC Pharmaceuticals (Jiangsu) Co., Ltd Main Business
Table 111. TC Pharmaceuticals (Jiangsu) Co., Ltd Latest Developments
Table 112. Lunan Pharm Basic Information, Ketorolac Injection Manufacturing Base, Sales Area and Its Competitors
Table 113. Lunan Pharm Ketorolac Injection Product Portfolios and Specifications
Table 114. Lunan Pharm Ketorolac Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 115. Lunan Pharm Main Business
Table 116. Lunan Pharm Latest Developments
Table 117. Yunnan Longhai Natured Plant Pharmaceutical Basic Information, Ketorolac Injection Manufacturing Base, Sales Area and Its Competitors
Table 118. Yunnan Longhai Natured Plant Pharmaceutical Ketorolac Injection Product Portfolios and Specifications
Table 119. Yunnan Longhai Natured Plant Pharmaceutical Ketorolac Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 120. Yunnan Longhai Natured Plant Pharmaceutical Main Business
Table 121. Yunnan Longhai Natured Plant Pharmaceutical Latest Developments
Table 122. Hairon Pharma Basic Information, Ketorolac Injection Manufacturing Base, Sales Area and Its Competitors
Table 123. Hairon Pharma Ketorolac Injection Product Portfolios and Specifications
Table 124. Hairon Pharma Ketorolac Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 125. Hairon Pharma Main Business
Table 126. Hairon Pharma Latest Developments
Table 127. Sichuan Medcalo Basic Information, Ketorolac Injection Manufacturing Base, Sales Area and Its Competitors
Table 128. Sichuan Medcalo Ketorolac Injection Product Portfolios and Specifications
Table 129. Sichuan Medcalo Ketorolac Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 130. Sichuan Medcalo Main Business
Table 131. Sichuan Medcalo Latest Developments
Table 132. Chengdu Brilliant Pharmaceuticals Basic Information, Ketorolac Injection Manufacturing Base, Sales Area and Its Competitors
Table 133. Chengdu Brilliant Pharmaceuticals Ketorolac Injection Product Portfolios and Specifications
Table 134. Chengdu Brilliant Pharmaceuticals Ketorolac Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 135. Chengdu Brilliant Pharmaceuticals Main Business
Table 136. Chengdu Brilliant Pharmaceuticals Latest Developments
Table 137. Yung Shin Pharm Basic Information, Ketorolac Injection Manufacturing Base, Sales Area and Its Competitors
Table 138. Yung Shin Pharm Ketorolac Injection Product Portfolios and Specifications
Table 139. Yung Shin Pharm Ketorolac Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 140. Yung Shin Pharm Main Business
Table 141. Yung Shin Pharm Latest Developments
Table 142. Tianjin Chase Sun Pharmaceutical Basic Information, Ketorolac Injection Manufacturing Base, Sales Area and Its Competitors
Table 143. Tianjin Chase Sun Pharmaceutical Ketorolac Injection Product Portfolios and Specifications
Table 144. Tianjin Chase Sun Pharmaceutical Ketorolac Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 145. Tianjin Chase Sun Pharmaceutical Main Business
Table 146. Tianjin Chase Sun Pharmaceutical Latest Developments
Table 147. ZISKA Pharmaceuticals Basic Information, Ketorolac Injection Manufacturing Base, Sales Area and Its Competitors
Table 148. ZISKA Pharmaceuticals Ketorolac Injection Product Portfolios and Specifications
Table 149. ZISKA Pharmaceuticals Ketorolac Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 150. ZISKA Pharmaceuticals Main Business
Table 151. ZISKA Pharmaceuticals Latest Developments
Table 1. Ketorolac Injection Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Ketorolac Injection Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of 15mg/ml
Table 4. Major Players of 30mg/ml
Table 5. Global Ketorolac Injection Sales by Concentration (2021-2026) & (K Units)
Table 6. Global Ketorolac Injection Sales Market Share by Concentration (2021-2026)
Table 7. Global Ketorolac Injection Revenue by Concentration (2021-2026) & ($ million)
Table 8. Global Ketorolac Injection Revenue Market Share by Concentration (2021-2026)
Table 9. Global Ketorolac Injection Sale Price by Concentration (2021-2026) & (US$/Unit)
Table 10. Global Ketorolac Injection Sale by Application (2021-2026) & (K Units)
Table 11. Global Ketorolac Injection Sale Market Share by Application (2021-2026)
Table 12. Global Ketorolac Injection Revenue by Application (2021-2026) & ($ million)
Table 13. Global Ketorolac Injection Revenue Market Share by Application (2021-2026)
Table 14. Global Ketorolac Injection Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Ketorolac Injection Sales by Company (2021-2026) & (K Units)
Table 16. Global Ketorolac Injection Sales Market Share by Company (2021-2026)
Table 17. Global Ketorolac Injection Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Ketorolac Injection Revenue Market Share by Company (2021-2026)
Table 19. Global Ketorolac Injection Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Ketorolac Injection Producing Area Distribution and Sales Area
Table 21. Players Ketorolac Injection Products Offered
Table 22. Ketorolac Injection Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Ketorolac Injection Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Ketorolac Injection Sales Market Share Geographic Region (2021-2026)
Table 27. Global Ketorolac Injection Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Ketorolac Injection Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Ketorolac Injection Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Ketorolac Injection Sales Market Share by Country/Region (2021-2026)
Table 31. Global Ketorolac Injection Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Ketorolac Injection Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Ketorolac Injection Sales by Country (2021-2026) & (K Units)
Table 34. Americas Ketorolac Injection Sales Market Share by Country (2021-2026)
Table 35. Americas Ketorolac Injection Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Ketorolac Injection Sales by Concentration (2021-2026) & (K Units)
Table 37. Americas Ketorolac Injection Sales by Application (2021-2026) & (K Units)
Table 38. APAC Ketorolac Injection Sales by Region (2021-2026) & (K Units)
Table 39. APAC Ketorolac Injection Sales Market Share by Region (2021-2026)
Table 40. APAC Ketorolac Injection Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Ketorolac Injection Sales by Concentration (2021-2026) & (K Units)
Table 42. APAC Ketorolac Injection Sales by Application (2021-2026) & (K Units)
Table 43. Europe Ketorolac Injection Sales by Country (2021-2026) & (K Units)
Table 44. Europe Ketorolac Injection Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Ketorolac Injection Sales by Concentration (2021-2026) & (K Units)
Table 46. Europe Ketorolac Injection Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Ketorolac Injection Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Ketorolac Injection Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Ketorolac Injection Sales by Concentration (2021-2026) & (K Units)
Table 50. Middle East & Africa Ketorolac Injection Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Ketorolac Injection
Table 52. Key Market Challenges & Risks of Ketorolac Injection
Table 53. Key Industry Trends of Ketorolac Injection
Table 54. Ketorolac Injection Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Ketorolac Injection Distributors List
Table 57. Ketorolac Injection Customer List
Table 58. Global Ketorolac Injection Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Ketorolac Injection Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Ketorolac Injection Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Ketorolac Injection Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Ketorolac Injection Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Ketorolac Injection Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Ketorolac Injection Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Ketorolac Injection Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Ketorolac Injection Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Ketorolac Injection Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Ketorolac Injection Sales Forecast by Concentration (2027-2032) & (K Units)
Table 69. Global Ketorolac Injection Revenue Forecast by Concentration (2027-2032) & ($ millions)
Table 70. Global Ketorolac Injection Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Ketorolac Injection Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Pfizer Basic Information, Ketorolac Injection Manufacturing Base, Sales Area and Its Competitors
Table 73. Pfizer Ketorolac Injection Product Portfolios and Specifications
Table 74. Pfizer Ketorolac Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Pfizer Main Business
Table 76. Pfizer Latest Developments
Table 77. Fresenius Kabi Basic Information, Ketorolac Injection Manufacturing Base, Sales Area and Its Competitors
Table 78. Fresenius Kabi Ketorolac Injection Product Portfolios and Specifications
Table 79. Fresenius Kabi Ketorolac Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Fresenius Kabi Main Business
Table 81. Fresenius Kabi Latest Developments
Table 82. Sun Pharmaceutical Basic Information, Ketorolac Injection Manufacturing Base, Sales Area and Its Competitors
Table 83. Sun Pharmaceutical Ketorolac Injection Product Portfolios and Specifications
Table 84. Sun Pharmaceutical Ketorolac Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Sun Pharmaceutical Main Business
Table 86. Sun Pharmaceutical Latest Developments
Table 87. Sagent Pharmaceuticals Basic Information, Ketorolac Injection Manufacturing Base, Sales Area and Its Competitors
Table 88. Sagent Pharmaceuticals Ketorolac Injection Product Portfolios and Specifications
Table 89. Sagent Pharmaceuticals Ketorolac Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Sagent Pharmaceuticals Main Business
Table 91. Sagent Pharmaceuticals Latest Developments
Table 92. Baxter Basic Information, Ketorolac Injection Manufacturing Base, Sales Area and Its Competitors
Table 93. Baxter Ketorolac Injection Product Portfolios and Specifications
Table 94. Baxter Ketorolac Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Baxter Main Business
Table 96. Baxter Latest Developments
Table 97. Glenmark Pharmaceutical Basic Information, Ketorolac Injection Manufacturing Base, Sales Area and Its Competitors
Table 98. Glenmark Pharmaceutical Ketorolac Injection Product Portfolios and Specifications
Table 99. Glenmark Pharmaceutical Ketorolac Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Glenmark Pharmaceutical Main Business
Table 101. Glenmark Pharmaceutical Latest Developments
Table 102. Sola Pharmaceutical Basic Information, Ketorolac Injection Manufacturing Base, Sales Area and Its Competitors
Table 103. Sola Pharmaceutical Ketorolac Injection Product Portfolios and Specifications
Table 104. Sola Pharmaceutical Ketorolac Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. Sola Pharmaceutical Main Business
Table 106. Sola Pharmaceutical Latest Developments
Table 107. TC Pharmaceuticals (Jiangsu) Co., Ltd Basic Information, Ketorolac Injection Manufacturing Base, Sales Area and Its Competitors
Table 108. TC Pharmaceuticals (Jiangsu) Co., Ltd Ketorolac Injection Product Portfolios and Specifications
Table 109. TC Pharmaceuticals (Jiangsu) Co., Ltd Ketorolac Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. TC Pharmaceuticals (Jiangsu) Co., Ltd Main Business
Table 111. TC Pharmaceuticals (Jiangsu) Co., Ltd Latest Developments
Table 112. Lunan Pharm Basic Information, Ketorolac Injection Manufacturing Base, Sales Area and Its Competitors
Table 113. Lunan Pharm Ketorolac Injection Product Portfolios and Specifications
Table 114. Lunan Pharm Ketorolac Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 115. Lunan Pharm Main Business
Table 116. Lunan Pharm Latest Developments
Table 117. Yunnan Longhai Natured Plant Pharmaceutical Basic Information, Ketorolac Injection Manufacturing Base, Sales Area and Its Competitors
Table 118. Yunnan Longhai Natured Plant Pharmaceutical Ketorolac Injection Product Portfolios and Specifications
Table 119. Yunnan Longhai Natured Plant Pharmaceutical Ketorolac Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 120. Yunnan Longhai Natured Plant Pharmaceutical Main Business
Table 121. Yunnan Longhai Natured Plant Pharmaceutical Latest Developments
Table 122. Hairon Pharma Basic Information, Ketorolac Injection Manufacturing Base, Sales Area and Its Competitors
Table 123. Hairon Pharma Ketorolac Injection Product Portfolios and Specifications
Table 124. Hairon Pharma Ketorolac Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 125. Hairon Pharma Main Business
Table 126. Hairon Pharma Latest Developments
Table 127. Sichuan Medcalo Basic Information, Ketorolac Injection Manufacturing Base, Sales Area and Its Competitors
Table 128. Sichuan Medcalo Ketorolac Injection Product Portfolios and Specifications
Table 129. Sichuan Medcalo Ketorolac Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 130. Sichuan Medcalo Main Business
Table 131. Sichuan Medcalo Latest Developments
Table 132. Chengdu Brilliant Pharmaceuticals Basic Information, Ketorolac Injection Manufacturing Base, Sales Area and Its Competitors
Table 133. Chengdu Brilliant Pharmaceuticals Ketorolac Injection Product Portfolios and Specifications
Table 134. Chengdu Brilliant Pharmaceuticals Ketorolac Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 135. Chengdu Brilliant Pharmaceuticals Main Business
Table 136. Chengdu Brilliant Pharmaceuticals Latest Developments
Table 137. Yung Shin Pharm Basic Information, Ketorolac Injection Manufacturing Base, Sales Area and Its Competitors
Table 138. Yung Shin Pharm Ketorolac Injection Product Portfolios and Specifications
Table 139. Yung Shin Pharm Ketorolac Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 140. Yung Shin Pharm Main Business
Table 141. Yung Shin Pharm Latest Developments
Table 142. Tianjin Chase Sun Pharmaceutical Basic Information, Ketorolac Injection Manufacturing Base, Sales Area and Its Competitors
Table 143. Tianjin Chase Sun Pharmaceutical Ketorolac Injection Product Portfolios and Specifications
Table 144. Tianjin Chase Sun Pharmaceutical Ketorolac Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 145. Tianjin Chase Sun Pharmaceutical Main Business
Table 146. Tianjin Chase Sun Pharmaceutical Latest Developments
Table 147. ZISKA Pharmaceuticals Basic Information, Ketorolac Injection Manufacturing Base, Sales Area and Its Competitors
Table 148. ZISKA Pharmaceuticals Ketorolac Injection Product Portfolios and Specifications
Table 149. ZISKA Pharmaceuticals Ketorolac Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 150. ZISKA Pharmaceuticals Main Business
Table 151. ZISKA Pharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. Picture of Ketorolac Injection
Figure 2. Ketorolac Injection Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Ketorolac Injection Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Ketorolac Injection Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Ketorolac Injection Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Ketorolac Injection Sales Market Share by Country/Region (2025)
Figure 10. Ketorolac Injection Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of 15mg/ml
Figure 12. Product Picture of 30mg/ml
Figure 13. Global Ketorolac Injection Sales Market Share by Concentration in 2026
Figure 14. Global Ketorolac Injection Revenue Market Share by Concentration (2021-2026)
Figure 15. Ketorolac Injection Consumed in Hospital
Figure 16. Global Ketorolac Injection Market: Hospital (2021-2026) & (K Units)
Figure 17. Ketorolac Injection Consumed in Clinics
Figure 18. Global Ketorolac Injection Market: Clinics (2021-2026) & (K Units)
Figure 19. Ketorolac Injection Consumed in Others
Figure 20. Global Ketorolac Injection Market: Others (2021-2026) & (K Units)
Figure 21. Global Ketorolac Injection Sale Market Share by Application (2025)
Figure 22. Global Ketorolac Injection Revenue Market Share by Application in 2026
Figure 23. Ketorolac Injection Sales by Company in 2026 (K Units)
Figure 24. Global Ketorolac Injection Sales Market Share by Company in 2026
Figure 25. Ketorolac Injection Revenue by Company in 2026 ($ millions)
Figure 26. Global Ketorolac Injection Revenue Market Share by Company in 2026
Figure 27. Global Ketorolac Injection Sales Market Share by Geographic Region (2021-2026)
Figure 28. Global Ketorolac Injection Revenue Market Share by Geographic Region in 2026
Figure 29. Americas Ketorolac Injection Sales 2021-2026 (K Units)
Figure 30. Americas Ketorolac Injection Revenue 2021-2026 ($ millions)
Figure 31. APAC Ketorolac Injection Sales 2021-2026 (K Units)
Figure 32. APAC Ketorolac Injection Revenue 2021-2026 ($ millions)
Figure 33. Europe Ketorolac Injection Sales 2021-2026 (K Units)
Figure 34. Europe Ketorolac Injection Revenue 2021-2026 ($ millions)
Figure 35. Middle East & Africa Ketorolac Injection Sales 2021-2026 (K Units)
Figure 36. Middle East & Africa Ketorolac Injection Revenue 2021-2026 ($ millions)
Figure 37. Americas Ketorolac Injection Sales Market Share by Country in 2026
Figure 38. Americas Ketorolac Injection Revenue Market Share by Country (2021-2026)
Figure 39. Americas Ketorolac Injection Sales Market Share by Concentration (2021-2026)
Figure 40. Americas Ketorolac Injection Sales Market Share by Application (2021-2026)
Figure 41. United States Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 42. Canada Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 43. Mexico Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 44. Brazil Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 45. APAC Ketorolac Injection Sales Market Share by Region in 2026
Figure 46. APAC Ketorolac Injection Revenue Market Share by Region (2021-2026)
Figure 47. APAC Ketorolac Injection Sales Market Share by Concentration (2021-2026)
Figure 48. APAC Ketorolac Injection Sales Market Share by Application (2021-2026)
Figure 49. China Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 50. Japan Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 51. South Korea Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 52. Southeast Asia Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 53. India Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 54. Australia Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 55. China Taiwan Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 56. Europe Ketorolac Injection Sales Market Share by Country in 2026
Figure 57. Europe Ketorolac Injection Revenue Market Share by Country (2021-2026)
Figure 58. Europe Ketorolac Injection Sales Market Share by Concentration (2021-2026)
Figure 59. Europe Ketorolac Injection Sales Market Share by Application (2021-2026)
Figure 60. Germany Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 61. France Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 62. UK Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 63. Italy Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 64. Russia Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 65. Middle East & Africa Ketorolac Injection Sales Market Share by Country (2021-2026)
Figure 66. Middle East & Africa Ketorolac Injection Sales Market Share by Concentration (2021-2026)
Figure 67. Middle East & Africa Ketorolac Injection Sales Market Share by Application (2021-2026)
Figure 68. Egypt Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 69. South Africa Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 70. Israel Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 71. Turkey Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 72. GCC Countries Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Ketorolac Injection in 2026
Figure 74. Manufacturing Process Analysis of Ketorolac Injection
Figure 75. Industry Chain Structure of Ketorolac Injection
Figure 76. Channels of Distribution
Figure 77. Global Ketorolac Injection Sales Market Forecast by Region (2027-2032)
Figure 78. Global Ketorolac Injection Revenue Market Share Forecast by Region (2027-2032)
Figure 79. Global Ketorolac Injection Sales Market Share Forecast by Concentration (2027-2032)
Figure 80. Global Ketorolac Injection Revenue Market Share Forecast by Concentration (2027-2032)
Figure 81. Global Ketorolac Injection Sales Market Share Forecast by Application (2027-2032)
Figure 82. Global Ketorolac Injection Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Ketorolac Injection
Figure 2. Ketorolac Injection Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Ketorolac Injection Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Ketorolac Injection Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Ketorolac Injection Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Ketorolac Injection Sales Market Share by Country/Region (2025)
Figure 10. Ketorolac Injection Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of 15mg/ml
Figure 12. Product Picture of 30mg/ml
Figure 13. Global Ketorolac Injection Sales Market Share by Concentration in 2026
Figure 14. Global Ketorolac Injection Revenue Market Share by Concentration (2021-2026)
Figure 15. Ketorolac Injection Consumed in Hospital
Figure 16. Global Ketorolac Injection Market: Hospital (2021-2026) & (K Units)
Figure 17. Ketorolac Injection Consumed in Clinics
Figure 18. Global Ketorolac Injection Market: Clinics (2021-2026) & (K Units)
Figure 19. Ketorolac Injection Consumed in Others
Figure 20. Global Ketorolac Injection Market: Others (2021-2026) & (K Units)
Figure 21. Global Ketorolac Injection Sale Market Share by Application (2025)
Figure 22. Global Ketorolac Injection Revenue Market Share by Application in 2026
Figure 23. Ketorolac Injection Sales by Company in 2026 (K Units)
Figure 24. Global Ketorolac Injection Sales Market Share by Company in 2026
Figure 25. Ketorolac Injection Revenue by Company in 2026 ($ millions)
Figure 26. Global Ketorolac Injection Revenue Market Share by Company in 2026
Figure 27. Global Ketorolac Injection Sales Market Share by Geographic Region (2021-2026)
Figure 28. Global Ketorolac Injection Revenue Market Share by Geographic Region in 2026
Figure 29. Americas Ketorolac Injection Sales 2021-2026 (K Units)
Figure 30. Americas Ketorolac Injection Revenue 2021-2026 ($ millions)
Figure 31. APAC Ketorolac Injection Sales 2021-2026 (K Units)
Figure 32. APAC Ketorolac Injection Revenue 2021-2026 ($ millions)
Figure 33. Europe Ketorolac Injection Sales 2021-2026 (K Units)
Figure 34. Europe Ketorolac Injection Revenue 2021-2026 ($ millions)
Figure 35. Middle East & Africa Ketorolac Injection Sales 2021-2026 (K Units)
Figure 36. Middle East & Africa Ketorolac Injection Revenue 2021-2026 ($ millions)
Figure 37. Americas Ketorolac Injection Sales Market Share by Country in 2026
Figure 38. Americas Ketorolac Injection Revenue Market Share by Country (2021-2026)
Figure 39. Americas Ketorolac Injection Sales Market Share by Concentration (2021-2026)
Figure 40. Americas Ketorolac Injection Sales Market Share by Application (2021-2026)
Figure 41. United States Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 42. Canada Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 43. Mexico Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 44. Brazil Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 45. APAC Ketorolac Injection Sales Market Share by Region in 2026
Figure 46. APAC Ketorolac Injection Revenue Market Share by Region (2021-2026)
Figure 47. APAC Ketorolac Injection Sales Market Share by Concentration (2021-2026)
Figure 48. APAC Ketorolac Injection Sales Market Share by Application (2021-2026)
Figure 49. China Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 50. Japan Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 51. South Korea Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 52. Southeast Asia Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 53. India Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 54. Australia Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 55. China Taiwan Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 56. Europe Ketorolac Injection Sales Market Share by Country in 2026
Figure 57. Europe Ketorolac Injection Revenue Market Share by Country (2021-2026)
Figure 58. Europe Ketorolac Injection Sales Market Share by Concentration (2021-2026)
Figure 59. Europe Ketorolac Injection Sales Market Share by Application (2021-2026)
Figure 60. Germany Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 61. France Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 62. UK Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 63. Italy Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 64. Russia Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 65. Middle East & Africa Ketorolac Injection Sales Market Share by Country (2021-2026)
Figure 66. Middle East & Africa Ketorolac Injection Sales Market Share by Concentration (2021-2026)
Figure 67. Middle East & Africa Ketorolac Injection Sales Market Share by Application (2021-2026)
Figure 68. Egypt Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 69. South Africa Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 70. Israel Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 71. Turkey Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 72. GCC Countries Ketorolac Injection Revenue Growth 2021-2026 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Ketorolac Injection in 2026
Figure 74. Manufacturing Process Analysis of Ketorolac Injection
Figure 75. Industry Chain Structure of Ketorolac Injection
Figure 76. Channels of Distribution
Figure 77. Global Ketorolac Injection Sales Market Forecast by Region (2027-2032)
Figure 78. Global Ketorolac Injection Revenue Market Share Forecast by Region (2027-2032)
Figure 79. Global Ketorolac Injection Sales Market Share Forecast by Concentration (2027-2032)
Figure 80. Global Ketorolac Injection Revenue Market Share Forecast by Concentration (2027-2032)
Figure 81. Global Ketorolac Injection Sales Market Share Forecast by Application (2027-2032)
Figure 82. Global Ketorolac Injection Revenue Market Share Forecast by Application (2027-2032)
